OMCL or HIMS: Which Is the Better Value Stock Right Now?

A Zacks analysis identifies Omnicell (OMCL) as a superior value stock opportunity compared to Hims & Hers Health, Inc. (HIMS) within the Medical Info Systems sector. OMCL holds a Zacks Rank #2 (Buy) and a Value grade of A, contrasting with HIMS's Zacks Rank #3 (Hold) and Value grade of D, supported by significantly more attractive valuation metrics including a forward P/E of 20.30 versus HIMS's 94.83, a PEG ratio of 3.26 versus 3.83, and a P/B ratio of 1.11 versus 22.76.

Analysis

Based on a comparative value analysis within the Medical Info Systems sector, Omnicell (OMCL) presents a significantly more attractive investment profile than Hims & Hers Health, Inc. (HIMS). This assessment is supported by the Zacks Rank system, which assigns OMCL a #2 (Buy) rating, indicating positive earnings estimate revisions, while HIMS holds a #3 (Hold) rating. The valuation disparity is stark: OMCL trades at a forward P/E ratio of 20.30, whereas HIMS commands a much higher multiple of 94.83. This valuation gap is further underscored by the price-to-book (P/B) ratios, with OMCL at a modest 1.11 compared to HIMS's elevated 22.76. While both companies are evaluated for growth via the PEG ratio, OMCL also holds a slight edge with a ratio of 3.26 versus 3.83 for HIMS. These quantitative factors culminate in OMCL receiving a top-tier 'A' grade for Value in the Zacks Style Scores system, in direct contrast to HIMS's 'D' grade, reinforcing the conclusion that OMCL is the superior option from a value investing standpoint.

Key Decisions for Investors

• Value-oriented investors should consider Omnicell (OMCL) due to its strong Buy rating, positive earnings estimate momentum, and significantly more attractive valuation metrics compared to its peer.
• Investors holding Hims & Hers Health (HIMS) should be cautious of its high valuation multiples, including a forward P/E of 94.83 and a P/B of 22.76, which contribute to its poor 'D' grade for value.
• When choosing between the two stocks, the data strongly favors OMCL for those prioritizing value, as its combination of lower multiples and a superior earnings outlook presents a more compelling risk-reward profile.